{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:59:55Z","timestamp":1764687595416},"reference-count":55,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T00:00:00Z","timestamp":1333324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated whether low\u2010dosed interferon alpha (IFNa) may augment the anti\u2010tumor potential of the histone deacetylase (HDAC)\u2010inhibitor valproic acid (VPA) on prostate cancer cells in vitro and in vivo. PC\u20103, DU\u2010145, or LNCaP prostate cancer cells were treated with VPA (1\u2009mM), IFNa (200\u2009U\/ml), or with the VPA\u2010IFNa combination. Tumor cell growth, cell cycle progression, and cell cycle regulating proteins were then investigated by the MTT assay, flow cytometry, and western blotting. Tumor cell adhesion to endothelium or to immobilized extracellular matrix proteins, as well as migratory properties of the cells, were evaluated. Integrin \u03b1 and \u03b2 adhesion molecules and alterations of cell signaling pathways were analyzed. Finally, effects of the drug treatment on prostate cancer growth in vivo were determined in the NOD\/SCID mouse model. VPA reduced tumor cell adhesion, migration, and growth in vitro. A much stronger anti\u2010cancer potential was evoked by the VPA\u2010IFNa combination, although IFNa in itself did not block growth or adhesion. The same effect was seen when tumor growth was evaluated in vivo. Molecular analysis revealed distinct elevation of histone H3 acetylation caused by VPA which was further up\u2010regulated by VPA\u2010IFNa, whereas IFNa alone did not alter H3 acetylation. The combinatorial benefit became obvious in Akt phosphorylation, p21 and p27 and integrin \u03b11, \u03b13, and \u03b21 expression. Application of low\u2010dosed IFNa to a VPA based regimen profoundly boosts the anti\u2010tumor properties of VPA. The combined use of VPA and low\u2010dosed IFNa may therefore be an innovative option in treating advanced prostate cancer. Prostate 72:1719\u20131735, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pros.22525","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T18:29:19Z","timestamp":1333477759000},"page":"1719-1735","source":"Crossref","is-referenced-by-count":24,"title":["Low dosed interferon alpha augments the anti\u2010tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion"],"prefix":"10.1002","volume":"72","author":[{"given":"Lukasz","family":"Hudak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Tezeeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Wedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Makarevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,2]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604199"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20022"},{"key":"e_1_2_8_4_2","first-page":"273","article-title":"Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells","volume":"48","author":"Waltregny D","year":"2004","journal-title":"Eur J Histochem"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.156"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4467"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605726"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-011-9386-8"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2010.12.017"},{"key":"e_1_2_8_10_2","article-title":"A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl\u20101 and Bcl\u2010(XL)","author":"Hwang JJ","journal-title":"Invest New Drugs"},{"key":"e_1_2_8_11_2","first-page":"97","article-title":"Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)\u2010C cells by valproic acid: Enhancement by combination with interferon\u2010alpha","volume":"20","author":"Cinatl J","year":"2002","journal-title":"Int J Oncol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-6-68"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0246-y"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00436.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2005.08.019"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2010.0902"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.364306"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111302200"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1846"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0309"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20423"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.66"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000030295"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990901)40:4<256::AID-PROS7>3.0.CO;2-I"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06054.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90445-2"},{"key":"e_1_2_8_28_2","first-page":"375","article-title":"De\u2010repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c\u2010Myc","volume":"33","author":"Wang LG","year":"2008","journal-title":"Int J Oncol"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.145"},{"key":"e_1_2_8_30_2","first-page":"911","article-title":"p27(kip1) and Ki\u201067 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer","volume":"19","author":"Revelos K","year":"2005","journal-title":"In Vivo"},{"key":"e_1_2_8_31_2","first-page":"5101","article-title":"Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer","volume":"23","author":"Ribal MJ","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000054004.08958.f3"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.12.6024"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3115"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.106658"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(91)90107-Q"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(97)00202-0"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003535"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05694"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(02)00287-3"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2010.20"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42328"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.4103\/1477-3163.48453"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01391.x"},{"key":"e_1_2_8_45_2","first-page":"347","article-title":"Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid","volume":"18","author":"Oertl A","year":"2006","journal-title":"Int J Mol Med"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400304"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21288"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0019"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701165200"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2011.597810"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22751"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.127"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21237"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.051649"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1223"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.394"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22525","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.22525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:50:20Z","timestamp":1700574620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.22525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,2]]},"references-count":55,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1002\/pros.22525"],"URL":"https:\/\/doi.org\/10.1002\/pros.22525","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,2]]}}}